Skip to main content
Erschienen in: Journal of Nephrology 5/2019

01.10.2019 | Original Article

Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1

verfasst von: Grazia Maria Virzì, Andrea Breglia, Chiara Castellani, Ghada Ankawi, Chiara Bolin, Massimo de Cal, Vito Cianci, Annalisa Angelini, Giorgio Vescovo, Claudio Ronco

Erschienen in: Journal of Nephrology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Cardiorenal syndrome type 1 (CRS type 1) is characterized by a rapid worsening of cardiac function leading to acute kidney injury. In this study, we evaluate the role of lipopolysaccharide (LPS) and various inflammatory markers in the developing acute kidney injury (AKI) in acute heart failure (AHF) patients.

Methods

We enrolled 31 AHF patients and 20 CRS type 1 (the cause of AKI was presumed to be related to cardiac dysfunction) and 17 healthy volunteers without AHF, AKI or CKD, as control group (CTR). We assessed levels of LPS, proinflammatory cytokines (TNF-α, IL-6, IL-18), and oxidative stress marker (myeloperoxidase, MPO).

Results

We observed a significant increase in LPS, TNF-α, IL-6, IL-18 and MPO levels in CRS type 1 and AHF group compared to CTR. LPS levels resulted significantly higher in CRS type 1 patients compared with AHF (118.2 pg/mL, IQR 77.8–217.6 versus 13.5 pg/mL, IQR 12.0–17.0, p = 0.008). We found a cytokines and oxidative stress dysregulation in CRS type 1 patients compared with AHF. Furthermore, we observed a strong positive significant correlation between LPS levels and IL-6 (Spearman’s rho = 0.79, p < 0.001), and IL-18 (Spearman’s rho = 0.77, p < 0.001) and MPO (Spearman’s rho = 0.80, p < 0.001), all confirm by simple linear regression analysis.

Conclusion

CRS type 1 patients presented an increased level of LPS, pro-inflammatory cytokines, and MPO. Furthermore, there is a direct correlation between LPS and pro-inflammatory cytokines and stress oxidative marker. LPS may play a role in the pathophysiology of CRS type 1 inducing inflammation, oxidative stress and finally kidney damage.
Literatur
2.
Zurück zum Zitat Ronco C, Cicoira M, McCullough PA (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60(12):1031–1042CrossRefPubMed Ronco C, Cicoira M, McCullough PA (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60(12):1031–1042CrossRefPubMed
3.
Zurück zum Zitat Virzi GM et al (2018) Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1. Cardiorenal Med 8(4):321–331CrossRefPubMedPubMedCentral Virzi GM et al (2018) Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1. Cardiorenal Med 8(4):321–331CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pastori S et al (2015) Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors. Cardiorenal Med 5(2):105–115CrossRefPubMedPubMedCentral Pastori S et al (2015) Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors. Cardiorenal Med 5(2):105–115CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Virzi GM et al (2018) Epigenetics: a potential key mechanism involved in the pathogenesis of cardiorenal syndromes. J Nephrol 31(3):333–341CrossRefPubMed Virzi GM et al (2018) Epigenetics: a potential key mechanism involved in the pathogenesis of cardiorenal syndromes. J Nephrol 31(3):333–341CrossRefPubMed
8.
9.
Zurück zum Zitat Virzi GM et al (2015) Pro-apoptotic effects of plasma from patients with cardiorenal syndrome on human tubular cells. Am J Nephrol 41(6):474–484CrossRefPubMed Virzi GM et al (2015) Pro-apoptotic effects of plasma from patients with cardiorenal syndrome on human tubular cells. Am J Nephrol 41(6):474–484CrossRefPubMed
10.
Zurück zum Zitat Virzi GM et al (2012) cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med 2(1):33–42CrossRefPubMedPubMedCentral Virzi GM et al (2012) cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med 2(1):33–42CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Charalambous BM et al (2007) Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28(1):15–23CrossRefPubMed Charalambous BM et al (2007) Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28(1):15–23CrossRefPubMed
12.
Zurück zum Zitat Goncalves S et al (2006) Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transpl 21(10):2788–2794CrossRef Goncalves S et al (2006) Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transpl 21(10):2788–2794CrossRef
13.
Zurück zum Zitat Niebauer J et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353(9167):1838–1842CrossRefPubMed Niebauer J et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353(9167):1838–1842CrossRefPubMed
14.
Zurück zum Zitat Colombo PC et al (2012) Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17(2):177–190CrossRefPubMed Colombo PC et al (2012) Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17(2):177–190CrossRefPubMed
15.
Zurück zum Zitat McMurray JJ et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847CrossRefPubMed McMurray JJ et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847CrossRefPubMed
16.
19.
Zurück zum Zitat von Haehling S et al (2009) Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 5(4):549–560CrossRef von Haehling S et al (2009) Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 5(4):549–560CrossRef
20.
Zurück zum Zitat Rosner MH, Ronco C, Okusa MD (2012) The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. Semin Nephrol 32(1):70–78CrossRefPubMed Rosner MH, Ronco C, Okusa MD (2012) The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. Semin Nephrol 32(1):70–78CrossRefPubMed
21.
Zurück zum Zitat Celis R, Torre-Martinez G, Torre-Amione G (2008) Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol 23(3):254–260CrossRefPubMed Celis R, Torre-Martinez G, Torre-Amione G (2008) Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol 23(3):254–260CrossRefPubMed
22.
Zurück zum Zitat Suffredini AF et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321(5):280–287CrossRefPubMed Suffredini AF et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321(5):280–287CrossRefPubMed
23.
Zurück zum Zitat Chiu CJ et al (1970) Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101(4):478–483CrossRefPubMed Chiu CJ et al (1970) Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101(4):478–483CrossRefPubMed
24.
Zurück zum Zitat Hassoun HT et al (2001) Post-injury multiple organ failure: the role of the gut. Shock 15(1):1–10CrossRefPubMed Hassoun HT et al (2001) Post-injury multiple organ failure: the role of the gut. Shock 15(1):1–10CrossRefPubMed
25.
Zurück zum Zitat Virzi GM et al (2017) Endotoxin effects on cardiac and renal functions and cardiorenal syndromes. Blood Purif 44(4):314–326CrossRefPubMed Virzi GM et al (2017) Endotoxin effects on cardiac and renal functions and cardiorenal syndromes. Blood Purif 44(4):314–326CrossRefPubMed
26.
Zurück zum Zitat Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13(2):85–94CrossRefPubMed Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13(2):85–94CrossRefPubMed
27.
Zurück zum Zitat Virzi GM et al (2016) Cardiorenal syndrome type 5 in sepsis: role of endotoxin in cell death pathways and inflammation. Kidney Blood Press Res 41(6):1008–1015CrossRefPubMed Virzi GM et al (2016) Cardiorenal syndrome type 5 in sepsis: role of endotoxin in cell death pathways and inflammation. Kidney Blood Press Res 41(6):1008–1015CrossRefPubMed
29.
Zurück zum Zitat Conraads VM et al (2004) Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6(4):483–491CrossRefPubMed Conraads VM et al (2004) Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6(4):483–491CrossRefPubMed
30.
Zurück zum Zitat Martinez-Pellus AE et al (1997) Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med 23(12):1251–1257CrossRefPubMed Martinez-Pellus AE et al (1997) Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med 23(12):1251–1257CrossRefPubMed
31.
Zurück zum Zitat Zager RA et al (2006) Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 290(6):F1453–F1462CrossRefPubMed Zager RA et al (2006) Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 290(6):F1453–F1462CrossRefPubMed
32.
Zurück zum Zitat Rangaswami J et al (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139:e840–e878CrossRefPubMed Rangaswami J et al (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139:e840–e878CrossRefPubMed
33.
Zurück zum Zitat Bannerman DD, Goldblum SE (1999) Direct effects of endotoxin on the endothelium: Barrier function and injury. Lab Invest 79:1181–1199PubMed Bannerman DD, Goldblum SE (1999) Direct effects of endotoxin on the endothelium: Barrier function and injury. Lab Invest 79:1181–1199PubMed
34.
Zurück zum Zitat Schneeberger PM, van Langevelde P, van Kessel KP, Vandenbroucke-Grauls CM, Verhoef J (1994) Lipopolysaccharide induces hyperadhesion of endothelial cells for neutrophils leading to damage. Shock 2:296–300CrossRefPubMed Schneeberger PM, van Langevelde P, van Kessel KP, Vandenbroucke-Grauls CM, Verhoef J (1994) Lipopolysaccharide induces hyperadhesion of endothelial cells for neutrophils leading to damage. Shock 2:296–300CrossRefPubMed
Metadaten
Titel
Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1
verfasst von
Grazia Maria Virzì
Andrea Breglia
Chiara Castellani
Ghada Ankawi
Chiara Bolin
Massimo de Cal
Vito Cianci
Annalisa Angelini
Giorgio Vescovo
Claudio Ronco
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 5/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-019-00613-2

Weitere Artikel der Ausgabe 5/2019

Journal of Nephrology 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.